Hematologic Malignancies
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hematologic Malignancies is an emerging landscape with 12 programs across 49 companies. The most active players are Sanofi, Prism Pharmaceuticals, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
92%
Small molecule
12 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 87% of 15 pipeline programs.
Analysis
Trial Status
218
clinical trials
Clinical Trials
Trial Activity
218 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)